A photo of Robert W. Frenck Jr.

Medical Director, Division of Infectious Diseases

Director, Vaccine Research Center

Professor, UC Department of Pediatrics

513-636-7839

513-636-3959

Board Certified

Best Doctors logo

My Biography & Research

Biography

The research that I’m most interested in is developing vaccines to prevent infections. Vaccines are the most impressive public health measure to reduce the rates of disease. I was inspired to pursue this area of pediatric patient care because infections are still the leading cause of death among children worldwide. I believe that finding methods to reduce infections among children will greatly enhance children's lives and help them grow up into healthy, happy adults.

Vaccines have saved more lives and averted more diseases than any other remedy that exists in medicine. Distributing vaccines around the globe has eliminated smallpox and has nearly eliminated polio. Furthermore, new vaccines are likely to prevent new infections, such as Ebola and COVID-19.

I am Director of the Gamble Center for Clinical Research, where my colleagues and I assess new vaccines and agents designed to prevent infections. I’m also the principal investigator of the Vaccine Treatment and Evaluation Unit (VTEU), which is funded by the National Institutes of Health (NIH).

At the Cincinnati Children’s Hospital Medical Center, we are one of nine VTEU sites that exist in the United States. Our hospital was selected as a VTEU site due to our extensive history of excellence in vaccine testing.

My research has been published in various journals, including Clinical Infectious Diseases, Open Forum Infectious Diseases, Lancet Infectious Diseases, and the Journal of Clinical Rheumatology: Practical Reports on Rheumatic and Musculoskeletal Disease. I’m an acknowledged authority in infectious diseases and have authored more than 125 articles and book chapters.

Clinical Interests

Vaccine research; enteric diseases; travel medicine

Research Interests

Enteric diseases; vaccinology

Academic Affiliation

Professor, UC Department of Pediatrics

Divisions

Infectious Diseases, Infectious Diseases



Blog Posts

Physicians Advocate for COVID-19 Vaccine Trials in Kids

Infectious Diseases and Vaccines

Physicians Advocate for COVID-19 Vaccine Trials in Kids

Robert W. Frenck Jr., MD, Paul Spearman, MD9/18/2020

Top 6 Reasons Why Clinical Trials Are Important

BlogResearch and Discoveries

Top 6 Reasons Why Clinical Trials Are Important

By Dr. Robert Frenck11/27/2018

Reminder: Incoming 7th & 12th Graders Need Meningococcal Vaccine

BlogVaccines

Reminder: Incoming 7th & 12th Graders Need Meningococcal Vaccine

By Dr. Robert Frenck7/28/2016

Vaccines

BlogVaccines

Vaccines: Their Own Worst Enemy

By Dr. Robert Frenck9/5/2013

My Locations

My Education

BA: University of California at San Diego, San Diego, CA, 1977.

MD: University of Texas Medical School at Houston, Houston, TX, 1981.

Internship and Residency: US Naval Hospital, Bethesda, MD, 1981-1984.

Fellowship: Pediatric Infectious Diseases, University of Texas Medical School at Houston, Houston, TX, 1987-1990.

My Publications

Persistence of immune responses through 36 months in healthy adults after vaccination with a novel Staphylococcus aureus 4-Antigen Vaccine (SA4Ag). Creech, CB; Frenck, RW; Fiquet, A; Feldman, R; Kankam, MK; Pathirana, S; Baber, J; Radley, D; Cooper, D; Eiden, J; et al. Open Forum Infectious Diseases. 2020; 7.

Consensus Report on Shigella Controlled Human Infection Model: Clinical Endpoints. MacLennan, CA; Riddle, MS; Chen, WH; Talaat, KR; Jain, V; Louis Bourgeois, A; Frenck, R; Kotloff, K; Porter, CK. Clinical Infectious Diseases. 2019; 69:S591-S595.

Consensus Report on Shigella Controlled Human Infection Model: Conduct of Studies. Talaat, KR; Louis Bourgeois, A; Frenck, RW; Chen, WH; MacLennan, CA; Riddle, MS; Suvarnapunya, AE; Brubaker, JL; Kotloff, KL; Porter, CK. Clinical Infectious Diseases. 2019; 69:S580-S590.

Safety and immunogenicity of a vaccine for extra-intestinal pathogenic Escherichia coli (ESTELLA): a phase 2 randomised controlled trial. Jr, FR W; Ervin, J; Chu, L; Abbanat, D; Spiessens, B; Go, O; Haazen, W; van den Dobbelsteen, G; Poolman, J; Thoelen, S; et al. Lancet Infectious Diseases. 2019; 19:631-640.

A Phase I trial to evaluate the safety and immunogenicity of WRSs2 and WRSs3; two live oral candidate vaccines against Shigella sonnei. Jr, FR W; Baqar, S; Alexander, W; Dickey, M; McNeal, M; El-Khorazaty, J; Baughman, H; Hoeper, A; Barnoy, S; Suvarnapunya, AE; et al. Vaccine. 2018; 36:4880-4889.

Cat-Scratch Disease, a Diagnostic Consideration for Chronic Recurrent Multifocal Osteomyelitis. Harry, O; Schulert, GS; Frenck, RW; Shapiro, AH; Woltmann, JL; Smith, JA; Grom, AA. Journal of Clinical Rheumatology: practical reports on rheumatic and musculoskeletal disease. 2018; 24:287-290.

Cat-Scratch Disease, a Diagnostic Consideration for Chronic Recurrent Multifocal Osteomyelitis. Harry, O; Schulert, GS; Jr, FR W; Shapiro, AH; Woltmann, JL; Smith, JA; Grom, AA. Journal of Clinical Rheumatology: practical reports on rheumatic and musculoskeletal disease. 2018; 24:287-290.

Giardia intestinalis (Giardiasis). Washam, M; Frenck, RW. Principles and Practice of Pediatric Infectious Diseases. : Elsevier; Elsevier; 2018.

Developing and utilizing controlled human models of infection. Porter, CK; Bourgeois, AL; Frenck, RW; Prouty, M; Maier, N; Riddle, MS. Vaccine. 2017; 35:6813-6818.

Lot-to-lot consistency, safety and immunogenicity of 3 lots of Haemophilus influenzae type b conjugate vaccine: results from a phase III randomized, multicenter study in infants. Klein, NP; Abu-Elyazeed, R; Cornish, M; Leonardi, ML; Weiner, LB; Silas, PE; Grogg, SE; Varman, M; Frenck, RW; Cheuvart, B; et al. Vaccine. 2017; 35:3564-3574.